Stephen L. Chan
Active 1993–2026
- 188
- Papers
- 33,756
- Citations
- 84
- h-index
- 172
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine67.6%
- Biochemistry, Genetics and Molecular Biology25.2%
- Immunology and Microbiology3.9%
- Engineering0.8%
- Computer Science0.4%
- Neuroscience0.4%
- Other1.7%
Topics
- Hepatocellular Carcinoma Treatment and Prognosis12.9%
- Cancer Immunotherapy and Biomarkers6.1%
- Cancer Genomics and Diagnostics4.5%
- Liver Disease Diagnosis and Treatment4.5%
- Cholangiocarcinoma and Gallbladder Cancer Studies4.4%
- Hepatitis B Virus Studies2.5%
- Other65.1%
Coauthors
- Masatoshi Kudo33
- Ann‐Lii Cheng31
- Vincent Wai‐Sun Wong31
- Paul B.S. Lai28
- Grace Lai‐Hung Wong26
- Thomas Yau26
- Anthony W.H. Chan25
- Shukui Qin23
- Frankie Mo22
- Henry Lik‐Yuen Chan22
- Ka‐Fai To22
- John Wong21
- Winnie Yeo20
- Robin Kate Kelley19
- Andrew X. Zhu17
- Anthony T.�C. Chan17
- Arndt Vogel17
- K.C. Allen Chan17
- Peiyong Jiang17
- Richard S. Finn17
- Yuk Ming Dennis Lo17
- Bruno Sangro16
- Ghassan K. Abou‐Alfa16
- Philippe Merle16
All papers
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Authors: Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Yuriy Ostapenko, Thomas Yau, Sérgio Jobim Azevedo, Marı́a Varela, Ann‐Lii Cheng, Shukui Qin, Peter R. Galle, Sajid Ali, Michelle Marcovitz, Mallory Makowsky, Philip He, John F. Kurland, Alejandra Negro, Bruno Sangro - NEJM Evidence 2022 cited by 1,432
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Authors: Shukui Qin, Stephen L. Chan, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Davide Melisi, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Linna Wang, Ahmed O. Kaseb, Arndt Vogel, Shukui Qin, Shukui Qin, Shukui Qin, Ahmed O. Kaseb, Arndt Vogel, Shanzhi Gu, Arndt Vogel, Zhenggang Ren, Xiaoyan Lin, Zhenggang Ren, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Jianping Xiong, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Margaryta Pisetska, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Kangsheng Gu, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bożena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, M. Nechaeva, Chia‐Jui Yen, Wei‐Wen Su, Yen‐Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gómez-Martín, Min‐Hee Ryu, Hansang Kim, Jeehyun Kim, Oleg Zarubenkov and 38 more - The Lancet 2023 cited by 679
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Authors: Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita - The Lancet Oncology 2018 cited by 2,536
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assénat, Eric Assenat, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Authors: Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, on behalf of the KEYNOTE-240 investigators - Journal of Clinical Oncology 2019 cited by 1,819
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Authors: Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek‐Yeol Ryoo, İrfan Çiçin, Philippe Merle, Yen-Hsun Chen, Joong‐Won Park, Jean-Frederic Blanc, Luigi Bolondi, Heinz‐Josef Klümpen, Stephen L. Chan, Vittorina Zagonel, Tiziana Pressiani, Min-Hee Ryu, Alan P. Venook, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley - New England Journal of Medicine 2018 cited by 2,337
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
Authors: Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi, Shinji Satomura, Mabel Teng, Helen L. Reeves, James O’Beirne, Richard Fox, Anna Skowrońska, Daniel H. Palmer, Winnie Yeo, Frankie Mo, Paul B.S. Lai, Mercedes Iñarrairaegui, Stephen L. Chan, Bruno Sangro, Rebecca A. Miksad, Toshifumi Tada, Takashi Kumada, Hidenori Toyoda - Journal of Clinical Oncology 2014 cited by 2,755
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Authors: Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng, Ahmed O. Kaseb, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, В. В. Бредер, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek‐Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Kamalika Banerjee, Saswati Hazra, Jonathan Fawcett, Thomas Yau - The Lancet Oncology 2022 cited by 522
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Authors: B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, John F. Kurland, Alejandra Negro, Ghassan K. Abou‐Alfa, Sérgio Santos de Azevêdo, Maria Ignez Braghiroli, Gustavo Girotto, Arinilda Campos Bragagnoli, Ricardo Branco, Adilson Faccio, Andrea Moretto, Nils Gunnar Skare, Jamille Dutra, Luciana Viola, Karina Vianna, Fernando Meton, Cláudia Vaz de Melo Sette, Amanda Faulhaber, Vincent C. Tam, Félix Couture, Jim Biagi, Hélène Castel, Karen Mulder, Yoo‐Joung Ko, Kevin Zbuk, Stephen Welch, Annie Beaudoin, Alexandra Heurgué, Éric Assenat, Isabelle Archambeaud, David Tougeron, Jean‐Marie Péron, Marine Gilabert, Jean–Pierre Bronowicki, Stéphane Cattan, Jean‐Frédéric Blanc, Mohamed Bouattour, Jean–Marc Phelip, Valérie Boige, Pierre Michel, Anne-Claire Frin, Enrico N. De Toni, Marie‐Luise Berres, Arndt Vogel, Thomas Berg, Thomas J. Ettrich, Dirk Waldschmidt, H. Wedemeyer, Marcus‐Alexander Wörns, Michael Bitzer, Karl-Heinz Weiss, George Lau, Stephen L. Chan, Thomas Yau, Y. Tai, Ann Shing Lee, Satheesh Chiradoni Thungappa, Lokesh K. N, Vikas Sureshchand Ostwal, Kattimani Kiran Ashok, Sushant Mittal, Hari Om Goyal, Sankar Srinivasan, Ghanashyam Biswas, Mallavarapu Mohan, Sewanti Limaye, Nirav Asarawala, Lorenza Rimassa, Alfredo Falcone, Luca Gianni, Antonio Gasbarrini, Bruno Daniele, Antonio Avallone, Giovanni Luca Frassineti, Fausto Roila, Masatoshi Kudo, Tomokazu Kawaoka, Manabu Morimoto, Yasuhiro Takikawa and 103 more - Annals of Oncology 2024 cited by 312
- Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Authors: Ann‐Lii Cheng, Chiun Hsu, Stephen L. Chan, Su-Pin Choo, Masatoshi Kudo - Journal of Hepatology 2020 cited by 565
- Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer
Authors: K.C. Allen Chan, John K. S. Woo, Ann D. King, Benny Zee, W.K. Lam, Stephen L. Chan, Sam W.I. Chu, Constance Mak, Irene O L Tse, Samantha Y.M. Leung, Gloria Chan, Edwin P. Hui, Brigette Ma, Rossa W. K. Chiu, Sing-Fai Leung, Andrew C. van Hasselt, Anthony T.�C. Chan, Yuk Ming Dennis Lo - New England Journal of Medicine 2017 cited by 779
- Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments
Authors: Kun Sun, Peiyong Jiang, K.C. Allen Chan, John Wong, Yvonne Kwun Yue Cheng, Raymond Liang, Wai‐Kong Chan, Edmond S.K., Stephen L. Chan, Suk Hang Cheng, Rebecca W.Y. Chan, Tong Yu, Simon S.M. Ng, Raymond Wong, David S.C. Hui, Tse Ngong Leung, Tak Yeung Leung, Paul B.S. Lai, Rossa W. K. Chiu, Yuk Ming Dennis Lo - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 cited by 809
- Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma
Authors: Peter R. Galle, Friedrich Foerster, Masatoshi Kudo, Stephen L. Chan, Josep M. Llovet, Shukui Qin, William R. Schelman, Sudhakar Chintharlapalli, Paolo Abada, Morris Sherman, Andrew X. Zhu - Liver International 2019 cited by 592
- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.
Authors: Riccardo Lencioni, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L. Chan, Yasuaki Arai, Jeong Heo, Ahn Mai, José J. Escobar, Yamil Alonso Lopez Chuken, Jung‐Hwan Yoon, Won Young Tak, Tanita Suttichaimongkol, Mohamed Bouattour, Shi‐Ming Lin, Magdalena Żotkiewicz, Stephanie I. Udoye, Gordon Cohen, Bruno Sangro - Journal of Clinical Oncology 2024 cited by 152
- Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients
Authors: Peiyong Jiang, Carol W. M. Chan, K.C. Allen Chan, Suk Hang Cheng, John Wong, Vincent Wai‐Sun Wong, Grace Lai‐Hung Wong, Stephen L. Chan, Tony Mok, Henry Lik‐Yuen Chan, Paul B.S. Lai, Rossa W. K. Chiu, Yuk Ming Dennis Lo - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 cited by 755
- Systemic treatment of hepatocellular carcinoma: An EASL position paper
Authors: Jordi Bruix, Stephen L. Chan, Peter R. Galle, Lorenza Rimassa, Bruno Sangro - Journal of Hepatology 2021 cited by 396
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Authors: Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo, George Lau, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Philip He, Alejandra Negro, Bruno Sangro - Journal of Clinical Oncology 2022 cited by 400
- A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
Authors: Weiqin Yang, Yu Feng, Jingying Zhou, Otto Ka-Wing Cheung, Jian Cao, Jing Wang, Wenshu Tang, Yalin Tu, Liangliang Xu, Feng Wu, Zhiwu Tan, Hanyong Sun, Yuan Tian, John Wong, Paul B.S. Lai, Stephen L. Chan, Anthony W.H. Chan, Patrick Tan, Zhiwei Chen, Joseph J.�Y. Sung, Kevin Y. Yip, Ka‐Fai To, Alfred S.L. Cheng - Science Translational Medicine 2021 cited by 162
- Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Authors: Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L. Chan, Masayuki Kurosaki, Namiki Izumi - Liver Cancer 2023 cited by 144
- A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Authors: Masatoshi Kudo, Kwang‐Hyub Han, Sheng-Long Ye, Jian Zhou, Yi‐Hsiang Huang, Shi-Ming Lin, Chung-Kwe Wang, Masafumi Ikeda, Stephen L. Chan, Su Pin Choo, Shiro Miyayama, Ann‐Lii Cheng - Liver Cancer 2020 cited by 307
- Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
Authors: Qinghe Zeng, Christophe Klein, Stefano Caruso, Pascale Maille, Daniela Allende, Beatriz Mínguez, Massimo Iavarone, Massih Ningarhari, Andrea Casadei-Gardini, Federica Pedica, Margherita Rimini, Riccardo Perbellini, Camille Boulagnon‐Rombi, Alexandra Heurgué, Marco Maggioni, Mohamed Rela, Mukul Vij, Sylvain Baulande, Patricia Legoix, Sonia Lameiras, Daniela Allende, Giuliana Amaddeo, Josepmaria Argemi, Sylvain Baulande, Aurélie Bèaufrere, María Bermúdez-Ramos, Camille Boulagnon‐Rombi, Jérôme Boursier, Léa Bruges, Julien Caldéraro, Julien Calderaro, Stefano Caruso, Stefano Caruso, A. García, Stephen L. Chan, Stephen Lam Chan, Antonio D'Alessio, Alba Díaz, Antonia Digklia, Jean‐François Dufour, Jean-François Dufour, Narmin Ghaffari Laleh, Narmin Ghaffari Laleh, Purva Gopal, Rondell P. Graham, Alexandra Heurgué, Massimo Iavarone, Mercedes Iñarrairaegui, Jakob Nikolas Kather, Jakob Nikolas Kather, Ismaïl Labgaa, Sonia Lameiras, Patricia Legoix, Marie Lequoy, Howard H.W. Leung, Howard Ho-Wai Leung, Marco Maggioni, Marco Maggioni, Juan Ignacio Marín, Guillermo Mendoza-Pacas, Sophie Michalak, Beatriz Mínguez, Omar S. M. El Nahhas, Omar S M El Nahhas, Pooja Navale, Massih Ningarhari, Massih Ningarhari, Valérie Paradis, Jean–Michel Pawlotsky, Jean-Michel Pawlotsky, Riccardo Perbellini, Riccardo Perbellini, Simon Peter, David James Pinato, Pompilia Radu, Hélène Regnault, María Reig, Maria Reig, Mohamed Rela, Lorenza Rimassa, Margherita Rimini, María Teresa Salcedo, María Teresa Salcedo, Bruno Sangro, Christine Sempoux, Tung‐Hung Su, Callie Torres, Nguyen H. Tran, Eric Trépo, Marı́a Varela, Gontran Verset, Gontran Verset, Arndt Vogel, Dominique Wendum, Qinghe Zeng, Qinghe Zeng, Marianne Ziol, Léa Bruges, Viviane Gnemmi, Jean-Charles Nault and 23 more - The Lancet Oncology 2023 cited by 109
- Epigenetic analysis of cell-free DNA by fragmentomic profiling
Authors: Qing Zhou, Guannan Kang, Peiyong Jiang, Rong Qiao, W.K. Lam, Stephanie C Y Yu, L Mary-Jane, Lu Ji, Suk Hang Cheng, Wanxia Gai, Wenlei Peng, Huimin Shang, Rebecca W.Y. Chan, Stephen L. Chan, Grace Lai‐Hung Wong, Linda T. Hiraki, Stefano Volpi, Vincent Wai‐Sun Wong, John Wong, Rossa W. K. Chiu, K.C. Allen Chan, Yuk Ming Dennis Lo - National Academy of Sciences, Proceedings of the National Academy of Sciences 2022 cited by 148
- Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
Authors: Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Chiaki Kagebayashi, Shinji Satomura, Nóra Schweitzer, Arndt Vogel, Michael P. Manns, Julia Benckert, Thomas Berg, Maria Ebker, Jan Best, Alexander Dechêne, Guido Gerken, JF Schlaak, Arndt Weinmann, Marcus A. Wörns, Peter R. Galle, Winnie Yeo, Frankie Mo, Stephen L. Chan, Helen L. Reeves, Trevor F. Cox, Philip J. Johnson - Clinical Gastroenterology and Hepatology 2016 cited by 323
- Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin
Authors: Kun Sun, Peiyong Jiang, Suk Hang Cheng, Timothy H.T. Cheng, John Wong, Vincent Wai‐Sun Wong, Simon S.M. Ng, Brigette Ma, Tak Yeung Leung, Stephen L. Chan, Tony Mok, Paul B.S. Lai, Henry Lik‐Yuen Chan, Hao Sun, K.C. Allen Chan, Rossa W. K. Chiu, Yuk Ming Dennis Lo - Genome Research 2019 cited by 263
